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Abstract
Objective To evaluate the association of chocolate consumption with
the risk of developing cardiometabolic disorders.
Design Systematic review and meta-analysis of randomised controlled
trials and observational studies.
Data sources Medline, Embase, Cochrane Library, PubMed, CINAHL,
IPA, Web of Science, Scopus, Pascal, reference lists of relevant studies
to October 2010, and email contact with authors.
Study selection Randomised trials and cohort, case-control, and cross
sectional studies carried out in human adults, in which the association
between chocolate consumption and the risk of outcomes related to
cardiometabolic disorders were reported.
Data extraction Data were extracted by two independent investigators,
and a consensus was reached with the involvement of a third. The
primary outcome was cardiometabolic disorders, including cardiovascular
disease (coronary heart disease and stroke), diabetes, and metabolic
syndrome. A meta-analysis assessed the risk of developing
cardiometabolic disorders by comparing the highest and lowest level of
chocolate consumption.
Results From 4576 references seven studies met the inclusion criteria
(including 114 009 participants). None of the studies was a randomised
trial, six were cohort studies, and one a cross sectional study. Large
variation was observed between these seven studies for measurement
of chocolate consumption, methods, and outcomes evaluated. Five of
the seven studies reported a beneficial association between higher levels
of chocolate consumption and the risk of cardiometabolic disorders. The
highest levels of chocolate consumption were associated with a 37%
reduction in cardiovascular disease (relative risk 0.63 (95% confidence
interval 0.44 to 0.90)) and a 29% reduction in stroke compared with the
lowest levels.
Conclusions Based on observational evidence, levels of chocolate
consumption seem to be associated with a substantial reduction in the
risk of cardiometabolic disorders. Further experimental studies are
required to confirm a potentially beneficial effect of chocolate
consumption.
Introduction
According to the World Health Organization, by 2030 nearly
23.6 million people will die from cardiovascular disorders.
1 2
Furthermore, about a fifth of the world’s adult population are
thought to have metabolic syndrome, a cluster of factors
associated with an increased risk of type 2 diabetes and
cardiovascular disease.
3 4 This increase in cardiometabolic
disorders exerts a great burden on people, healthcare
organisations,andsocietyingeneral.However,cardiometabolic
disorders are largely preventable, and a better understanding of
the factors associated in their physiopathogenesis and
implementation of interventions to modify these factors will be
critical in tackling the current epidemic.
Diet is one of the key lifestyle factors involved in the genesis,
prevention, and control of cardiometabolic disorders. Cocoa
products containing flavonol have been shown to have an
encouragingpotentialtohelppreventcardiometabolicdisorders.
5
Recent studies (both experimental and observational) have
suggested that chocolate consumption has a positive influence
on human health, with antioxidant, antihypertensive,
anti-inflammatory,anti-atherogenic,andanti-thromboticeffects
as well as influence on insulin sensitivity, vascular endothelial
function, and activation of nitric oxide.
6-16 These beneficial
effects have been confirmed in recent reviews and
meta-analyses, supporting the positive role of cacao and cocoa
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Research
RESEARCHproducts on cardiovascular risk factors such as blood pressure,
cholesterol levels, atherosclerosis, and insulin resistance.
17-25
However, most of the existing evidence is on intermediate
factors of cardiovascular disorders, and it remains unclear
whether chocolate consumption is related to reductions in hard
cardiovascular outcomes (such as myocardial infarction and
stroke).
We carried out a systematic review and meta-analysis of the
scientificliteraturetoevaluatetheassociationbetweenchocolate
intake and the risk of developing cardiometabolic disorders,
including cardiovascular disease (stroke, heart failure, and
myocardial infarction), diabetes, and metabolic syndrome. We
also evaluated whether this association would differ by type of
cardiometabolic disorder, sex, and study characteristics.
Methods
Wecarriedoutasystematicreviewandmeta-analysisofstudies
that evaluated the association between chocolate consumption
and cardiometabolic disorders in adults. Between June 2010
and 5 October 2010 (last date searched) we searched Medline
(1950 to present), Embase (1980 to present), the Cochrane
Library (1960 to present), Scopus (1996 to present), Scielo
(1997topresent),Webofknowledge(1970topresent),AMED
(1985 to present), and CINHAL (1981 to present).
We used combinations of text words and thesaurus terms that
included cacao[Mesh], cacao[Title/Abstract]*, chocolate,
chocolate*[Title/Abstract], cocoa, cocoa*[Title/Abstract],
cardiovascular diseases [Mesh], cardiovascular disease,
cardiovascular, coronary artery disease [Mesh], atherosclerosis
[Mesh], coronary disease [Mesh], coronary heart disease,
coronary, myocardial, ischaemic heart disease, ischaemic heart
disease*[Title/Abstract],ischemicheartdisease,ischemicheart
disease*[Title/Abstract], Heart Failure[Mesh], myocardial
infarction [Mesh], myocardial ischemia [Mesh], stroke, stroke
[Mesh], cerebral stroke, stroke, brain vascular accident,
cerebrovascular stroke, cerebrovascular accident, cerebral
vascular, cerebral vascular accident, cerebrovascular CVA,
metabolicsyndromeX[Mesh],metabolicsyndrome,metabolic
cardiovascularsyndrome*[title/abstract],diabetestype2,diabeti,
diabete,diabet*[title/abstract],diabetesmellitus[Mesh],diabetes
mellitus, type 2 [Mesh].
Studies were included if they were randomised controlled trials
or cohort, case-control, or cross sectional studies; carried out
in adults (≥18 years old); studied the effects of levels of
chocolate consumption; the outcomes of interest were related
tocardiometabolicdisorders(cardiovasculardisease,myocardial
infarction,stroke,ischaemicheartdisease,heartfailure,diabetes,
and metabolic syndrome); and had no language restriction (if
necessary,localscientistsfluentintheoriginallanguagehelped
with translation). We excluded studies including only pregnant
participants;letters,abstracts,systematicreviews,meta-analysis,
ecological studies, and conference proceedings; and studies
carried out in non-humans.
Two independent reviewers working in pairs (AB-L and OHF,
JS, LJ, or SW) screened the titles and abstracts of the initially
identified studies to determine if they satisfied the selection
criteria. Any disagreements were resolved through consensus
or consultation with a third reviewer. Full text articles were
retrieved for the selected titles. Reference lists of the retrieved
articles were searched for additional publications. We also
contacted the authors of the retrieved papers directly for any
additional and unpublished studies. The retrieved studies were
assessed again by two independent authors (AB-L and OHF)
to ensure that they satisfied the inclusion criteria.
Data extraction
We designed a data collection form before the implementation
of the search strategy. Two independent reviewers used this
formtoextracttherelevantinformationfromtheselectedstudies
(AB-L and OHF). The data collection form included questions
onqualitativeaspectsofthestudies(suchasdateofpublication,
design,geographicaloriginandsetting,fundingsource,selection
criteria, patient samplings, and location of research group),
participantcharacteristics(suchnumberincludedintheanalysis,
age range, mean age, sex, ethnicity, recruitment procedures,
residential region, socioeconomic status, comorbidities, and
drug treatment), characteristics of the exposure or intervention
evaluated (such as type, method used to measure), and
information on the reported outcomes (such as measure of
disease association, type of outcome, outcome assessment
method, type of statistical analysis, adjustment variables).
Quality evaluation
Two independent reviewers (AB-L and OHF) evaluated the
quality of the studies included using a modified scoring system
thatwascreatedonthebasisofarecentlyusedsystem(designed
with reference to MOOSE, QUATSO, and STROBE) that
allowed a total score of 0–6 points (6 reflecting the highest
quality).
26 The system allocates one point each for (a) any
justification given for the cohort; (b) appropriate inclusion and
exclusion criteria were used; (c) diagnosis of cardiometabolic
disorderswasnotsolelybasedonselfreporting;(d)participants’
usualchocolateconsumptionwasassessedwithavalidatedtool;
(e) adjustments were made for age, sex, body mass index, and
smoking status; and (f) any other adjustments were done (such
as for physical activity, dietary factors).
Statistical analysis
We evaluated the differences between low and high chocolate
consumption on outcomes such as diabetes, incidence of
cardiovasculardisease,cardiovascularmortality,coronaryheart
disease,incidenceofstroke,anddeathsfromstroke.Wepooled
results using a random effects model, and we did tests for
heterogeneity and publication bias. Results were expressed as
pooled relative risks with 95% confidence intervals.
For each study, we compared the group with highest chocolate
consumption against the group with the lowest consumption.
Hazard ratios, relative risks, and odds ratios were assumed to
approximate the same measure of relative risk. By pooling the
study-specific estimates using a random effects model that
included between-study heterogeneity (parallel analyses used
fixed effect models), we calculated summary relative risks. We
carried out a cumulative meta-analysis by outcome in which
the pooled estimate of the association reported was updated
each time the results of a new study were included. Possible
sources of heterogeneity of relative risks were examined using
the Cochran-Mantel-Haenszel test for the null hypothesis of no
effect (relative risk=1), and the Mantel-Haenszel common
relative risk estimate.
27 The I
2 (which quantifies the percentage
of variation attributable to heterogeneity) was reported as a
measure of consistency across the studies.
Finally, we assessed publication bias by using a funnel plot and
Begg’s test to find out whether there was a bias towards
publication of studies with positive results among studies with
a smaller sample size.
28
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RESEARCHSubgroup analysis
To test the robustness of our findings, we repeated the
meta-analysisbydifferentoutcomes(anycardiovasculardisease,
diabetes, heart failure, and stroke), sex, and types of chocolate
(dark, milk, white).
Results
Overall, 4576 references were initially identified: 4563 from
electronicdatabasesand13frombibliographiesandexperts(fig
1⇓).AmongthedatabasesmostofthestudiescamefromScopus
(n=2654) and Embase (n=584). Of the 4576 references, 1221
wereduplicates(identifiedusingreferencemanagerandmanual
checks) and were excluded. After the initial screening of the
titleandabstract,afurther3302citationswereexcluded,leaving
53 articles for retrieval. Full text assessment of these articles
resulted in seven eligible studies that were included in our
analyses. Of the 46 excluded, 14 did not report levels of
chocolateconsumption,14didnotrecordtheeffectsofchocolate
intake on outcomes related to our study,
11 12 17 20 21 29-37 and the
remaining18wereletters,abstracts,orconferenceproceedings.
Characteristics of included studies
Table1⇓showsthecharacteristicsofthesevenselectedstudies,
which included 114 009 participants.
7 9 10 13-16 One was a cross
sectional study carried out in the United States. The other six
were cohort studies carried out in Europe (Germany,
Netherlands, and Sweden), Asia (Japan), and North America.
Six studies were carried out in the community and one in
hospitalinpatients.Participants’agerangedfrom25to93years.
Although most of the participants were white, one study also
included Hispanic and African-American people, and one
studied an Asian population. Four studies included men and
women,twoincludedonlywomen,andoneincludedonlymen.
In three studies, participants were taking drug treatment,
including hormone replacement therapy and drugs for
cardiovascular disease (calcium channel blockers, β blockers,
angiotensin converting enzyme inhibitors, diuretics, digitalis,
nitrates, and aspirin). No study reported the effect of chocolate
consumptiononmetabolicsyndrome,andtheoutcomesreported
includedmyocardialinfarction,diabetes,cardiovasculardisease,
coronaryheartdisease,heartfailure,andstroke(table2⇓).More
than one outcome was measured in four studies, and for these
the measure of association for each outcome was included in
the analysis.
Allofthestudiesreportedoverallchocolateconsumptionasthe
exposure (not reported separately whether dark or white
chocolate), and one reported cocoa consumption.
7 Six studies
appliedfoodfrequencyquestionnairestomeasuretheexposure,
with some minor modifications from original questionnaires
using a single item from the food frequency questionnaire that
asked about consumption of chocolate bars, snacks, or pieces.
The remaining paper used estimates of chocolate consumption
in patient diaries cross checked with dietary history adapted
from populations.
Levels of chocolate consumption included the consumption of
chocolatebars,chocolatedrinks,andchocolatesnacks(including
confectionery, biscuits, desserts, nutritional supplements, and
candy bars). All the studies reported chocolate consumption in
adifferentmanner:threecategories(never,onceamonthtoless
than once a week, and once a week or more)
16; two categories
(less than once a week, once a week or more)
14; four categories
(never, less than once a month to less than once a week, once
a week, and more than once a week)
13; thirds of cacao intake
7;
five categories (none, 1–3/month, 1–2/week, 3–6/week, and
>1/day)
15; fourths of chocolate consumption (ranging from 1.7
g/day to 7.5 g/day)
9; and four categories (none, 1–3/month,
1–4/week, and >5/week).
10 Considering the heterogeneity in
reportingandmeasuringchocolateconsumption,wedecidedto
usethelowestandhighestcategoriestomeasuretheassociation
of chocolate consumption with cardiometabolic
disorders.
7 9 10 13-16
The range of time to follow-up for the cohort studies was
between eight and 16 years. All studies were funded by public
institutions, with no industry funding reported in the
acknowledgements sections. Although no study scored the
highest level of quality (maximum 6), overall the level was
adequate,withsixofthesevenstudiesscoring5andonescoring
4 (table 1⇓).
Association of chocolate consumption with
cardiometabolic disorders by outcome
Of the seven included studies, five (14 875 participants with a
high level of chocolate consumption) reported a significant
inverse association between chocolate intake and
cardiometabolic disorders (table 2, fig 2⇓). Of the 13 measures
of association used, 12 (92%) reported a beneficial association
of higher chocolate consumption (compared with lowest
consumption level) on the prevention of cardiometabolic
disorders. The remaining measure was the association of
chocolate consumption with heart failure (relative risk 1.23
(95% confidence interval 0.73 to 2.08)). All the measures of
association reported were adjusted for age and multiple
additional variables, including sex, body mass index, physical
activity, smoking, dietary factors (including coffee
consumption),andeducation.Somewerealsoadjustedfordrug
use (table 2⇓).
Onpoolingtheretrievedmeasuresofassociation,wefoundthat
high chocolate consumption was associated with about a third
decrease in the risk of cardiometabolic disorders—37% in the
case of any cardiovascular disease (relative risk 0.63 (95%
confidence interval 0.44 to 0.90)) and 29% in the case of stroke
prevention (0.71 (0.52 to 0.98)) (see fig 2⇓). No significant
association was observed in relation to heart failure (relative
risk 0.95 (0.61 to 1.48)).
Only one study evaluated the association between chocolate
consumption and diabetes, and it reported a beneficial
association in Japanese men and women (hazard ratios 0.65
(0.43 to 0.97) and 0.73 (0.48 to 1.13) respectively).
Publication bias
Funnel plot analysis showed no evidence of significant
publication bias (see extra figure on bmj.com).
Discussion
Higher levels of chocolate consumption were associated with
a reduction of about a third in the risk of cardiometabolic
disorders in our meta-analysis. This beneficial association was
significant for any cardiovascular disease (37% reduction),
diabetes (31% reduction, based on one publication), and stroke
(29% reduction), but no significant association was found in
relation to heart failure.
Fiveofthesevenstudiesincludedinthismeta-analysisreported
asignificantreductionintheriskofdevelopingcardiometabolic
disorders associated with higher levels of chocolate intake (one
on cocoa intake), even after adjustment for potential
confounders,includingage,physicalactivity,bodymassindex,
smoking status, dietary factors, education, and drug use.
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RESEARCHAlthoughwedidnotfindanyexperimentalstudies(randomised
controlled trials) evaluating the effect of chocolate on hard
cardiometabolic outcomes, our findings corroborate those of
previous meta-analyses of experimental and observational
studies in different populations related to risk factors for
cardiometabolicdisorders.
18 19 23-25Thesefavourableeffectsseem
mainly mediated by the high content of polyphenols present in
cocoa products and probably accrued through increasing the
bioavailability of nitric oxide, which subsequently might lead
to improvements in endothelial function, reductions in platelet
function, and additional beneficial effects on blood pressure,
insulin resistance, and blood lipids.
5
Necessary cautions
Beyond the caution needed in interpretation of data from
observational studies, one must also consider other aspects
associated with chocolate consumption. For instance, the high
energydensityofcommerciallyavailablechocolate(about2100
kJ(500kcal)/100g)meansexcessiveconsumptionwillprobably
induceweightgain,ariskfactorforhypertension,dyslipidaemia,
diabetes, and cardiometabolic disorders in general.
5 Hence the
high sugar and fat content of commercially available chocolate
should be considered, and initiatives to reduce it might permit
an improved exposure to the beneficial effect of chocolate.
However, the articles included in our analysis did not provide
the information needed to evaluate any potential differences
between different types of chocolate in the associations with
cardiometabolic disorders.
Exploration of heterogeneity
Although our studies included populations with and without
priorcardiovasculardisease,thesmallnumbersmeantwecould
not evaluate whether the associations found would differ in
terms of primary or secondary prevention. Nevertheless, data
from previous meta-analyses evaluating the effect of chocolate
intakeonintermediatefactorssuggestthatthebeneficialeffects
might be similarly beneficial among those with existing
cardiovascular disease as it is for those without these
conditions.
19 23 24 Further studies are required to confirm this.
We found no papers studying the relation between chocolate
consumption and the risk of developing metabolic syndrome,
and we identified only one study showing the relation between
diabetesandchocolateintake(apositiveassociation,especially
in men).
16 Although we aimed to evaluate the potential sex
differences in the association of chocolate intake with
cardiometabolicdisorders,thelackofstudiesreportingstratified
results by sex prevented this.
Only two of the studies included evaluated the potential
association of chocolate intake with the risk of heart failure.
Bothstudiesfoundnosignificanteffect.
13 15Thiscouldberelated
to the nature of the development of heart failure, as it generally
occurs towards the end of the spectrum of cardiovascular
disorders in terms of natural course and severity of disease.
Eventually, this result may need to be examined by further
studies.
Strengths and limitations of the review
Previous studies have evaluated the effect of chocolate intake
on cardiovascular risk factors and prevention of cardiovascular
disorders,
18 19 22-25 but our systematic review is the first attempt
to pull together the different existing studies that evaluated the
associations of chocolate consumption with cardiometabolic
events.Oneofthereasonsforthisisthattheavailableliterature
on this topic is limited and novel, with all studies published in
the past four years and with more than half of the included
studies published in 2010. We expect further studies will be
done to confirm or refute the results of our analyses. Of special
importance, experimental evidence will be needed before any
levelofcausalitycanbeinferredfromtheexistingfindings,and
residual confounding could be considered as a potential
explanation for the associations observed.
Considering the limited data available, any conclusions should
be cautious. Nevertheless, the current evidence on hard and
intermediateoutcomessuggeststhatchocolatemightbeaviable
instrument in the prevention of cardiometabolic disorders if
consumed in moderation and if efforts are made to reduce the
sugar and fat content of currently available products. Beyond
this, considering the acceptability and popularity of chocolate,
theapplicabilityofitsconsumptionasarecommendationmight
suit multiple populations. This would be particularly relevant
in developing countries, where most of the cacao plantations
and production sites are located (the top producers of cacao
include African countries such as the Ivory Coast, Asian
countriessuchasIndonesia,andSouthAmericancountriessuch
as Brazil) but where the processed form might not be easily
available. Chocolate could therefore provide a natural,
convenient, and generally welcome prophylactic against the
growing epidemics of cardiometabolic disorders in developing
countries.
Generalisation of our findings is hampered by the geographical
origin of the included studies, as they were mainly carried out
in Europe and the United States. Future studies should provide
detailed information about different populations or different
ethnicgroupsinothergeographicallocationsandfromdifferent
socioeconomic levels. Moreover, it is important to assess the
effectofdifferenttypesofchocolate,aswellasthemeasurement
and amounts. Given the considerable heterogeneity in the
information from the original studies, it was not possible for us
to establish a clear dose-response relation between chocolate
intake and the risk of cardiometabolic disorders. Furthermore,
although most of the included studies adjusted for relevant
factors that could confound the association between chocolate
consumption and cardiometabolic disorders, the potential
confounding effect of these factors might still be prevalent.
Chocolate intake is likely to be underestimated by consumers,
and may be underestimated to a larger extent by those with a
higher body mass index. As people with a higher body mass
index are also more likely to have a cardiovascular disease
outcome,thentheunderestimationoftheirchocolateintakemay
induce an artificial inverse association between chocolate and
risk of cardiovascular disease.
Other factors that might hamper the quality of recording
chocolate consumption also need consideration. These include
thepotentialeffectofrecallbiasandthechallengesofrecording
snacks (which might include chocolate) as these are generally
under-reported compared with meals.
Conclusions
Cocoaproductsandchocolatehavebeenconsumedandenjoyed
by humans for centuries. Although over-consumption can have
harmful effects, the existing studies generally agree on a
potential beneficial association of chocolate consumption with
alowerriskofcardiometabolicdisorders.Ourfindingsconfirm
this, and we found that higher levels of chocolate consumption
might be associated with a one third reduction in the risk of
developing cardiovascular disease. Corroboration is now
required from further studies, especially experimental studies
to test causation rather than just association.
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RESEARCHWhat is already known on this topic
The prevalence of cardiometabolic disorders is increasing worldwide
Cocoa and chocolate have been suggested to have antihypertensive, anti-inflammatory, anti-atherogenic, and
anti-thrombotic effects
What this study adds
This meta-analysis of six cohort studies and one cross sectional study showed increased chocolate intake was significantly
associated with a reduced risk of cardiovascular disease
This beneficial association was significant for any cardiovascular disease (37% reduction), diabetes (31%), and stroke
(29%), but no significant association was found in relation to heart failure
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Table 1| Characteristics of studies included in meta-analysis of association of chocolate consumption with risk of cardiometabolic disorders
Outcome measures
Follow-up
(years)
Participants
Quality
score*
Study
design
Intervention
measures Study (setting) Characteristics
No in
analysis
Incidence of diabetes 10 Asian men and women 13 540 5 Cohort Consumption of coffee,
tea, chocolate snacks,
and caffeine content
Oba et al 2010
16
(Japan)
Coronary heart disease, stroke,
cardiovascular mortality
16 White postmenopausal
women
34 489 5 Cohort Flavonoid intake Mink et al 2007
14 (USA)
Cardiovascular mortality,
recurrent myocardial infarction,
stroke, congestive heart failure
8 White men and women
who had had an acute
myocardial infarction
1169 4 Cohort Chocolate consumption Janszky et al 2009
13
(Sweden)
Blood pressure, cardiovascular
mortality
15 White men 470 5 Cohort Cocoa intake Buijsse et al 2006
7
(Netherlands)
Incidence of heart failure 9 Middle aged and elderly
white women
31 823 5 Cohort Chocolate intake Mostofsky et al 2010
15
(Sweden)
Blood pressure, myocardial
infarction, incident
cardiovascular disease, stroke
10 White men and women 19 357 5 Cohort Chocolate consumption Buijsse et al 2010
9
(Germany)
Coronary heart disease NA Men and women of mixed
ethnicity
4970 5 Cross
sectional
Chocolate consumption Djousse et al 2010
10
(USA)
*Score 0-6, with 6 representing high quality.
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RESEARCHTable 2| Measures of disease association and adjustments to outcomes in studies of association of chocolate consumption with risk of
cardiometabolic disorders
Measures of association (95% CI) Adjustments Outcome measures Study
Hazard ratios 0.65 (0.43 to 0.97) men,
0.73 (0.48 to 1.93) women
Age, smoking status, body mass index, physical activity, education
(years), alcohol intake, total energy intake, fat intake, menopausal
status (in women)
Incidence of diabetes Oba et al 2010
16
Rate ratios 0.98 (0.88 to 1.10), 0.85
(0.70 to 1.03)
Age, energy consumption, marital status, education, blood pressure,
diabetes, body mass index, waist to hip ratio, physical activity,
smoking, oestrogen use
Coronary heart disease
mortality, stroke mortality
Mink et al 2007
14
Hazard ratios 0.78 (0.52 to 1.16), 0.34
(0.17 to 0.70), 0.86 (0.54 to 1.37),
0.62 (0.33 to 1.16)
Age, sex, smoking status, obesity, physical inactivity, alcohol
consumption (g/day), filtered coffee intake (cups/day), educational
attainment, sweet score
Congestive heart failure,
cardiovascular disease mortality,
recurrent myocardial infarction,
stroke
Janszky et al 2009
13
Relative risk 0.50 (0.32 to 0.78) Age; body mass index; smoking status; alcohol consumption;
physical activity; aspirin use; anticoagulant use; diet prescription
(Y/N); consumption of: vegetables, fruit, low and medium fat dairy,
meat, sugar confectionery other than chocolate, cookies, savoury
foods, nuts, and coffee; and total calorie intake
Cardiovascular disease mortality Buijsse et al 2006
7
Rate ratio 1.23 (0.73 to 2.08) Age, education, body mass index, physical activity, smoking status,
living alone, HRT intake, alcohol intake, family history of myocardial
infarction before 60 years, self reported history of hypertension, and
cholesterol level
Heart failure Mostofsky et al 2010
15
Relative risks 0.73 (0.47 to 1.18), 0.52
(0.30 to 0.89)
Age, sex, alcohol intake, employment status, body mass index, waist
circumference, smoking status, occupational physical activity, sports
cycling, education, and total energy intake
Myocardial infarction, stroke Buijsse et al 2010
9
Odds ratio 0.43 (0.27 to 0.68) Age, sex, dietary linoleic acid intake, education, exercise, smoking
status, alcohol intake, fruit and vegetables intake, energy intake,
non-chocolate candy intake
Coronary heart disease Djousse et al 2010
10
HRT=hormone replacement therapy
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Fig 1 Flow diagram for selection of studies
Fig 2 Relative risks for cardiovascular disease, heart failure, and stroke in adults with higher levels of chocolate consumption
compared with lower levels
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